# Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)

Study · id `cardio:ct-nct04857840` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04857840](<https://clinicaltrials.gov/study/NCT04857840>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04857840

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 419 participants.

## Technical summary

Registry record NCT04857840. Randomized; double masking; primary purpose treatment. Start 2021-08-05 (actual); primary completion 2023-01-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 419 participants (enrolled count; ClinicalTrials.gov record NCT04857840, source copy `cardio:ctgov-nct04857840-2023-01-17`, retrieved 2026-10-26)
- Started: 2021-08-05 (actual) (ClinicalTrials.gov record NCT04857840, source copy `cardio:ctgov-nct04857840-2023-01-17`, retrieved 2026-10-26)
- Primary completion: 2023-01-09 (actual) (ClinicalTrials.gov record NCT04857840, source copy `cardio:ctgov-nct04857840-2023-01-17`, retrieved 2026-10-26)
- Completion: 2023-01-09 (actual) (ClinicalTrials.gov record NCT04857840, source copy `cardio:ctgov-nct04857840-2023-01-17`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT04857840, source copy `cardio:ctgov-nct04857840-2023-01-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04857840-2023-01-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH)
- Acronym: REFRESH
- Condition: Hypertension (HTN)
- Intervention (Drug): Firibastat (QGC001) Period 1
- Lead sponsor: Quantum Genomics SA
- Lead sponsor class: INDUSTRY
- Collaborator: PRA Health Sciences
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Resistant hypertension (`cardio:resistant-hypertension`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Quantum Genomics SA (`cardio:org-quantum-genomics-sa`)

## Provenance

Content hash: 57abacfc1a2e7c3e9dc9e9e4a1b72df6978b9acb49ca06c80be5891ce004d26f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
